The Global Partnership for Zero Leprosy (GPZL) is a coalition committed to ending leprosy, also known as Hansen’s disease. Our members include individuals and organizations who share our triple-zero vision of no disease, no disability, and no discrimination or stigma.

Our Impact

  • organizational members
  • individual members
  • country partnerships
  • best practices

The Challenge

  • 200,000 people
    diagnosed each year
  • 5 million people
    living with leprosy-related disability and stigma
  • 150 countries
    with active transmission
  • 130 laws
    discriminate against people who have experienced leprosy

Our Strategy


  • Country Partnership

    We work with country governments and convene international and in-country stakeholders to map leprosy and scale up deployment of zero transmission tools.


  • Research Acceleration

    We build consensus on critical research to interrupt transmission and steer researchers, investors and developers on the path towards zero transmission research priorities.


  • Prioritizing People

    We promote a person-centred approach to leprosy services and set global standards for the prioritization of people and their rights in the journey towards zero leprosy.

learn more

Zero Leprosy Toolkit

The Zero Leprosy Toolkit is a free set of field-tested best practices designed to support countries in their work toward ending leprosy and its associated disabilities and stigma.

Browse all best practices

Subscribe to Newsletter

Receive monthly updates on our progress toward zero leprosy and opportunities to get involved.

Sign up

Recent News

10 March 2025

Call for Nominations – Representatives National Leprosy Programs for GPZL Members’ Assembly

The Global Partnership for Zero Leprosy (GPZL) is seeking nominations for Representatives of National Leprosy Programs to serve on its Members’ Assembly for a two-year term, renewable once. The term will begin on 1 April 2025.

Read more >


10 March 2025

GPZL Seeks Supply Chain Consultant

With the support of GPZL partner organizations, the consultant will conduct a comprehensive assessment of MDT, Clofazimine, Prednisolone, and Rifampicin supply chain challenges in the selected countries, identifying inefficiencies, key barriers, and opportunities for improvement.

Read more >